STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 95 filers reported holding STOKE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $104,528 | -57.6% | 26,530 | +14.5% | 0.00% | – |
| Q2 2023 | $246,265 | -74.2% | 23,167 | -79.8% | 0.00% | – |
| Q1 2023 | $954,000 | +433536.4% | 114,467 | +379.8% | 0.00% | – |
| Q4 2022 | $220 | -99.9% | 23,859 | +1.2% | 0.00% | – |
| Q3 2022 | $302,000 | +1.7% | 23,568 | +4.8% | 0.00% | – |
| Q2 2022 | $297,000 | -27.9% | 22,498 | +14.7% | 0.00% | – |
| Q1 2022 | $412,000 | +5.6% | 19,608 | +20.8% | 0.00% | – |
| Q4 2021 | $390,000 | +4.0% | 16,234 | +10.2% | 0.00% | – |
| Q3 2021 | $375,000 | -19.0% | 14,728 | +7.2% | 0.00% | – |
| Q2 2021 | $463,000 | +24.1% | 13,745 | +43.3% | 0.00% | – |
| Q1 2021 | $373,000 | 0.0% | 9,589 | +59.4% | 0.00% | – |
| Q4 2020 | $373,000 | +139.1% | 6,016 | +32.1% | 0.00% | – |
| Q3 2020 | $156,000 | +39.3% | 4,554 | -2.9% | 0.00% | – |
| Q2 2020 | $112,000 | -11.1% | 4,691 | -14.8% | 0.00% | – |
| Q1 2020 | $126,000 | +46.5% | 5,505 | +82.3% | 0.00% | – |
| Q4 2019 | $86,000 | +34.4% | 3,019 | +0.6% | 0.00% | – |
| Q3 2019 | $64,000 | – | 3,001 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 296,822 | $7,551,000 | 1.86% |
| RTW INVESTMENTS, LP | 3,644,248 | $92,710,000 | 1.40% |
| Cormorant Asset Management, LP | 1,278,276 | $32,519,000 | 1.32% |
| Redmile Group, LLC | 2,381,958 | $60,597,000 | 1.06% |
| HighVista Strategies LLC | 47,594 | $1,211,000 | 0.80% |
| Birchview Capital, LP | 15,000 | $382,000 | 0.26% |
| GILDER GAGNON HOWE & CO LLC | 1,123,355 | $28,578,000 | 0.15% |
| Artal Group S.A. | 250,000 | $6,360,000 | 0.14% |
| Tekla Capital Management LLC | 99,263 | $2,525,000 | 0.08% |
| Casdin Capital, LLC | 120,000 | $3,053,000 | 0.08% |